小叶型与导管型组织学对转移性乳腺癌总生存的影响:法国回顾性多中心队列研究
基于法国ESME多中心数据库,13,111例转移性乳腺癌患者中ILC占13.8%、IDC占86.2%;多变量分析显示ILC总生存更差(HR 1.31,95%CI 1.20-1.42,p<0.0001),一线无进展生存也更差(HR 1.15,95%CI 1.07-1.22,p<0.0001),且独立于激素受体和HER2状态。
要点
- 在转移性乳腺癌中,小叶型组织学与更差的总生存独立相关(HR 1.31,95%CI 1.20-1.42,p<0.0001)。
- 小叶型患者一线无进展生存亦更差(HR 1.15,95%CI 1.07-1.22,p<0.0001)。
- 小叶型与导管型的总生存差异随分子亚型不同:三阴性更好(HR 0.79),激素受体阳性/HER2阴性更差(HR 1.17),HER2阳性相似(HR 0.88)。
核心结论
- 小叶型组织学是转移性乳腺癌女性独立的不良预后因素。
- 小叶型转移性乳腺癌可被视为一个特定实体。
- 需要专门的前瞻性研究来制定这些患者的个体化管理策略。
研究设计与样本
- 法国国家多中心流行病学策略与医疗经济学(ESME)数据平台回顾性多中心队列研究。
- 主要目的为比较浸润性小叶癌(ILC)与浸润性导管癌(IDC)转移性乳腺癌患者的总生存,采用多变量分析和倾向性评分匹配两种方法校正主要预后因素。
- 次要目的为比较一线无进展生存(PFS1)并描述患者与肿瘤特征。
- ESME数据库共16,703例转移性乳腺癌患者,其中13,111例符合本分析全部纳入标准。
主要发现
- 多变量分析中,ILC患者总生存较IDC患者更差(HR 1.31;95%CI 1.20-1.42;p<0.0001)。
- 多变量分析中,ILC患者PFS1较IDC患者更差(HR 1.15;95%CI 1.07-1.22;p<0.0001),且独立于激素受体和HER2状态。
- 与IDC相比,ILC患者中三阴性转移性乳腺癌总生存更好(HR 0.79;95%CI 0.64-0.98;p=0.0302)。
- 与IDC相比,ILC患者中激素受体阳性/HER2阴性转移性乳腺癌总生存更差(HR 1.17;95%CI 1.08-1.27;p=0.0001),HER2阳性者相似(HR 0.88;95%CI 0.67-1.15;p=0.3455)。
临床怎么用
- 原文结论指出小叶型组织学是转移性乳腺癌独立的不良预后因素,可被视为特定实体。
- 作者认为需要专门的前瞻性研究来制定这些患者的个体化管理策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The impact of the histological lobular subtype on overall survival (OS) in metastatic breast cancer (MBC) is still under debate, with very few data available. PATIENTS AND METHODS: Using the French national multicentre Epidemiological Strategy and Medico Economics [ESME]) data platform, the primary objective was to compare the OS of patients with invasive lobular carcinoma (ILC) versus invasive ductal carcinoma (IDC) MBC, with adjustment on the main prognostic factors using two approaches: multivariable analysis and matching with a propensity score. Secondary objectives were to compare first-line progression-free survival (PFS1) and describe patients and tumour characteristics. RESULTS: Of the 16,703 patients with MBC in the ESME database, 13,111 met all inclusion criteria for the present analysis. One-thousand eight-hundred and four (13.8%) patients had ILC and 11.307 (86.2%) IDC. In the multivariable analysis, patients with ILC had a worse OS [hazard ratio (HR): 1.31; 95%CI 1.20-1.42; p < 0.0001] and a worse PFS1 (HR: 1.15; 95%CI 1.07-1.22; p < 0.0001) as compared with those with IDC, independently of hormone receptor and HER2 status. Interestingly, OS was better (HR 0.79; 95% confidence interval [CI] 0.64-0.98; p = 0.0302), worse (HR: 1.17; 95%CI 1.08-1.27; p = 0.0001) or similar (HR: 0.88; 95%CI 0.67-1.15; p = 0.3455) in patients with ILC with triple-negative, hormone receptor-positive/HER2-negative and HER2-positive MBC, respectively, compared with patients with IDC. CONCLUSION: Lobular histology is an independent adverse prognostic factor among women with MBC. ILC MBC could be considered a specific entity. Dedicated prospective studies are needed to tailor the management of these patients.
引用
- Dalenc F, Lusque A, De La Motte Rouge T, et al. Impact of lobular versus ductal histology on overall survival in metastatic breast cancer: a French retrospective multicentre cohort study. Eur J Cancer. 2022. PMID: 35176614. doi:10.1016/j.ejca.2021.12.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。